LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital

,

Source: LexaGene Holdings Inc

BEVERLY, Mass., June 05, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGFTSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has placed its first beta prototype into Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA.  Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health.

“This placement marks a very significant milestone for the Company and for the diagnostics industry.  We have generated a long list of interested users who want to test our technology.  From this list, we selected Mass Vet to be our first site due to their reputation for being pioneers and thought leaders in veterinary medicine.  The doctors at Mass Vet are eager to test our cutting-edge technology to provide the best possible treatment for their patients,” said Dr. Jack Regan, CEO and Founder of LexaGene. “Following the placement at Mass Vet, we will continue placing our devices at various other sites throughout the United States as part of our ongoing beta test program. This will enable potential customers to experience the technology in their own facility so that they can compare LX-generated results to their standard testing methods. We are confident these users will quickly appreciate the benefits of our technology and this will help seed future sales.”

The beta LX prototype is expected to identify the presence of bacteria in the overwhelming majority of urinary tract infections.  In addition, the beta prototype will simultaneously screen samples for common antibiotic resistance factors providing veterinarians the information they need to select the best treatment for their patients.

“Emergency and critical care veterinarians are eagerly awaiting the commercialization of an accurate instrument that can identify the cause of an infection and whether any antibiotic resistance factors are detected.  We are very excited to have the opportunity to first test LexaGene’s technology.  It is amazing that their instrument returns results so quickly, as we are used to waiting 3 days to get results back.  Shortening the turn-around time for quality results will lead to much better patient care,” said Dr. Chand Khanna DVM, PhD, DACVIM (Onc), DACVP (Hon), Chief Science Officer of Ethos Veterinary Health and President of Ethos Discovery.

A video interview with Dr. Jack Regan regarding this news can be viewed here.

We are pleased to announce that LexaGene will host a webinar tomorrow, Thursday, June 6th at 11 AM EST to provide an overview of the Company.  The webinar signup can be accessed at this link.

To be added to the LexaGene email distribution list, please subscribe on the Company website.

 


About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

About Ethos Veterinary Health
Ethos Veterinary Health is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information, ethosvet.com.

Media Contacts
Nicole Ridgedale
Director of Corporate Marketing, LexaGene
800.215.1824 ext 206
nridgedale@lexagene.com

Investor Relations
Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207
jadelaar@lexagene.com

New study boasts 90% accuracy when using PARR to diagnose canine lymphoma

,

Article originally published in NEWStat, an American Animal Hospital Association Publication 

Written by Tony McReynolds


Who measures the measurements? Who diagnoses the diagnostics? In short, who assays the assays?

Veterinarians have been using polymerase chain reaction for antigen receptor rearrangement (PARR), a readily available molecular assay that helps diagnose some kinds of canine lymphoma, for years. But no one really knew how accurate those assays were—because none have undergone a truly rigorous benchmarking study to determine the accuracy of PARR assays in general, regardless of the manufacturer.

Until now.

In a study published in the Journal of Veterinary Internal Medicine, Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen) found that their version of the test, called ePARR, was more than 90% accurate among a range of lymphoma sample types.

The results of the ePARR test study are based on an analysis of 180 dogs with cancer. The researchers used ePARR to confirm whether the dogs in the study had lymphoma and then to determine what type they had.

“We’re very excited about it,” Chand Khanna, DVM, PhD, DACVIM (Oncology), DACVP (Honorary), told NEWStat. Khanna is chief science officer of Ethos Veterinary Health, president of Ethos Discovery (a 501(c)3 independent not-for-profit incubator of scientific innovation), and co-senior author of the study.

Khanna emphasized that ePARR is not a new kind of assay but rather a new brand of assay, and the way it works to diagnose lymphoma isn’t different from what’s currently out there. He said the big takeaway here is the accuracy of the new study, which he calls “very rigorous.” He pointed out that the sheer number of dogs tested “well exceeds what has been done” in previous studies.

“What’s new is that doctors can offer [PARR assays] with a greater confidence in the performance of the assay than was possible before,” Khanna said.

Most dogs with lymphoma can be easily diagnosed using a simple microscopic evaluation of cells taken from the lymph node, so PAAR isn’t a first-line diagnostic test. However, a small minority of dogs yield tissue samples that display unusual features under the microscope, which makes some clinicians hesitant to begin treatment for lymphoma. In those cases, Khanna said, “you need a much more rigorous confirmatory test.”

PAAR, for example.

NEWStat asked Barbara Biller, DVM, DACVIM, retired associate professor of oncology at the Flint Animal Cancer Center at Colorado State University and practicing veterinarian at Boulder Road Veterinary Specialists in Lafayette, Colorado, what the study meant for veterinarians dealing with suspected cases of canine lymphoma.

“It’s further validation of [PARR],” Biller said. “We don’t need it to diagnose most cases of lymphoma but when we do need it, it can be really helpful. [The study clears up] some of the questions we have as far as how accurate it is for different samples.”

“This is the kind of data we need in this profession,” Biller added. “You have an organized, systematic evaluation of a technique. And it’s really good to see that kind of research.”

 

Read the article on NEWStat